Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Calliditas Therapeutics AB (publ) CALT
$25.08
+$0.31 (1.25%)
На 18:02, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
760446351.00000000
-
week52high
25.64
-
week52low
10.82
-
Revenue
802879000
-
P/E TTM
-17
-
Beta
1.29134100
-
EPS
-1.54000000
-
Last Dividend
0.00000000
-
Next Earnings Date
17 мая 2023 г. в 04:00
Описание компании
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 20 дек 2021 г. |
| Stifel | Buy | Buy | 30 июн 2020 г. |
| Jefferies | Buy | Buy | 30 июн 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Calliditas: Low Cash And Unconvincing Pipeline
Seeking Alpha
17 янв 2023 г. в 08:34
CALT has an approved product in the US and EU in IgAN. However, the rest of its pipeline consists of an unconvincing single product with a history of failure.
New Strong Sell Stocks for January 6th
Zacks Investment Research
06 янв 2023 г. в 09:02
CALT, CVGW and DFH have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2023.
Calliditas' Kinpeygo Receives CHMP Backing For Kidney Disease
Benzinga
19 мая 2022 г. в 15:28
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional approval for Calliditas Therapeutics AB's (NASDAQ: CALT) Kinpeygo for primary immunoglobulin A (IgA) nephropathy (IgAN). The.